Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 72 hrs
The global angina pectoris drugs market is expected to be valued at USD 10.6 Billion by 2022, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.
Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.
Further key findings from the report suggest:
The global angina pectoris drugs market is expected to be valued at USD 10.6 Billion by 2022, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.
Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.
Further key findings from the report suggest:
- The U.S. dominated this space by accounting for more than 33.0% of the market share in 2016 due to increasing incidence of cardiac disorders and presence of key manufacturers in the U.S.
- The angina pectoris drug market is commercially meaningful, however branded sales are in decline as generics dominate a larger portion of prescriptions. Though the market is fragmented, key players such as Sanofi, Gilead, AstraZeneca and Pfizer hold significant market positions
- Biosimilar development is emerging as a promising market opportunity in angina pectoris therapeutics. Multiple biosimilars have gained approvals in the U.S., European and Indian markets
- China offers strong opportunity for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform and supportive 12th Five-Year Plan measure, which targets biotechnology as the key development sector
- Changing regulatory scenario in the U.S. presents favorable environment for disruptive technologies in healthcare. In the EU, the new Clinical Trials Regulation (EU No. 536/2014) will impact clinical trials of Advanced Therapy Medicinal Products. Industry concerns regarding ROIs on novel therapies remains a challenge to drug development.
- Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen and GlaxoSmithKline
CHAPTER 1 RESEARCH METHODOLOGY
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. 1 Chapter Summary
3.1.1 Disease Primer/101
3.1.2 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU 5)
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 1 Chapter Summary
4.2 Market, by Therapeutic Class
4.3 Market Size and Forecast 2016 - 2022
4.4 Market Share Distribution, by Company 2016 - 2022
4.5 Sales Performance, by Drug Class
4.6 Market Dynamics among Leading Brands
4.7 Patent Expiry Analysis
4.8 Angina Pectoris Market: Drivers and Restraints
4.8.1 Drivers
4.8.2 Challenges
4.9 M&A, Deal Landscape (2013- 2017 YTD)
4.9.1 Mergers & Acquisitions
4.9.2 Deals Landscape
4.10 Evolution of Biosimilars
4.11 Emerging Markets
4.12 Pricing and Reimbursement Scenario
4.13 Angina Pectoris Sector SWOT
CHAPTER 5 PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 1 Chapter Summary
6.2 Sanofi
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Sales Forecast Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.4.2 Catalysts & Events Calendar
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Gilead Sciences
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 SWOT
6.4 AstraZeneca
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Amgen
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 GlaxoSmithKline
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2022
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.5 Pipeline Analysis & Overview
6.6.6 SWOT
6.7 Eli Lilly
6.7.1 Company Overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales Through 2022
6.7.4 Strategic Initiatives
6.7.4.1 Key Company News Flow
6.7.5 SWOT
6.8 Pfizer
6.8.1 Company Overview
6.8.2 Current Product Portfolio
6.8.3 Product Forecast Sales Through 2022
6.8.4 Strategic Initiatives
6.8.4.1 Key Company News Flow
6.8.5 Pipeline Analysis & Overview
6.8.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.3 Emerging Companies & New Technology Platforms
7.4 The Road Ahead
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. 1 Chapter Summary
3.1.1 Disease Primer/101
3.1.2 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU 5)
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 1 Chapter Summary
4.2 Market, by Therapeutic Class
4.3 Market Size and Forecast 2016 - 2022
4.4 Market Share Distribution, by Company 2016 - 2022
4.5 Sales Performance, by Drug Class
4.6 Market Dynamics among Leading Brands
4.7 Patent Expiry Analysis
4.8 Angina Pectoris Market: Drivers and Restraints
4.8.1 Drivers
4.8.2 Challenges
4.9 M&A, Deal Landscape (2013- 2017 YTD)
4.9.1 Mergers & Acquisitions
4.9.2 Deals Landscape
4.10 Evolution of Biosimilars
4.11 Emerging Markets
4.12 Pricing and Reimbursement Scenario
4.13 Angina Pectoris Sector SWOT
CHAPTER 5 PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 1 Chapter Summary
6.2 Sanofi
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Sales Forecast Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.4.2 Catalysts & Events Calendar
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Gilead Sciences
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 SWOT
6.4 AstraZeneca
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Amgen
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 GlaxoSmithKline
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2022
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.5 Pipeline Analysis & Overview
6.6.6 SWOT
6.7 Eli Lilly
6.7.1 Company Overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales Through 2022
6.7.4 Strategic Initiatives
6.7.4.1 Key Company News Flow
6.7.5 SWOT
6.8 Pfizer
6.8.1 Company Overview
6.8.2 Current Product Portfolio
6.8.3 Product Forecast Sales Through 2022
6.8.4 Strategic Initiatives
6.8.4.1 Key Company News Flow
6.8.5 Pipeline Analysis & Overview
6.8.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.3 Emerging Companies & New Technology Platforms
7.4 The Road Ahead
LIST OF TABLES
Table 1 Stable Angina Pectoris Total Estimated Prevalence Rate in Top Seven Markets
Table 2 U.S. Patents for Current Angina Pectoris Drugs
Table 3 Average Cost of CAD Treatment in Patients With and Without Angina Pectoris
Table 4 Table Number and Cost of Prescriptions for Angina Pectoris in the UK
Table 5 R&D Pipeline Overview
Table 6 Late Stage Pipeline
Table 7 Pipeline Forecast
Table 8 Off Patent Products in Angina Pectoris Market
Table 9 Sales Forecast, 2016 - 2022
Table 10 Sales Forecast, 2016 - 2022
Table 11 Off Patent Products in Angina Pectoris Market
Table 12 Sales Forecast, 2016 - 2022
Table 13 Sales Forecast, 2016 - 2022
Table 14 Sales Forecast, 2016 - 2022
Table 15 Off Patent Products in Angina Pectoris Market
Table 16 Sales Forecast, 2016 - 2022
Table 17 Off Patent Products in Angina Pectoris Market
Table 18 Sales Forecast, 2016 - 2022
Table 1 Stable Angina Pectoris Total Estimated Prevalence Rate in Top Seven Markets
Table 2 U.S. Patents for Current Angina Pectoris Drugs
Table 3 Average Cost of CAD Treatment in Patients With and Without Angina Pectoris
Table 4 Table Number and Cost of Prescriptions for Angina Pectoris in the UK
Table 5 R&D Pipeline Overview
Table 6 Late Stage Pipeline
Table 7 Pipeline Forecast
Table 8 Off Patent Products in Angina Pectoris Market
Table 9 Sales Forecast, 2016 - 2022
Table 10 Sales Forecast, 2016 - 2022
Table 11 Off Patent Products in Angina Pectoris Market
Table 12 Sales Forecast, 2016 - 2022
Table 13 Sales Forecast, 2016 - 2022
Table 14 Sales Forecast, 2016 - 2022
Table 15 Off Patent Products in Angina Pectoris Market
Table 16 Sales Forecast, 2016 - 2022
Table 17 Off Patent Products in Angina Pectoris Market
Table 18 Sales Forecast, 2016 - 2022
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Age Specific Prevalence of Stable Angina Pectoris in the U.S.+ Top Five EU Markets (Germany, U.K., France, Italy, Spain)
Fig. 8 Age and Gender Specific Prevalence of Stable Angina Pectoris in the U.S.
Fig. 9 Age and Gender Specific Incidence of Stable Angina Pectoris in the U.S.
Fig. 10 Age and Gender Specific Prevalence of Angina Pectoris in the U.K.
Fig. 11 Age and Gender Specific Incidence of Angina Pectoris in the U.K.
Fig. 12 Age and Gender Specific Prevalence of Angina Pectoris in Japan
Fig. 13 Angina Pectoris Treatment Market by Therapeutic Class
Fig. 14 Regional Market Size, 2016 - 2022
Fig. 15 Market Shares Distribution, 2016 - 2022
Fig. 16 Sales by Therapeutic Class, 2016 - 2022
Fig. 17 Branded Sales by Regions, 2016 - 2022
Fig. 18 Angina Pectoris Sector SWOT
Fig. 19 Sanofi SWOT Analysis
Fig. 20 Gilead Sciences SWOT Analysis
Fig. 21 AstraZeneca SWOT Analysis
Fig. 22 Amgen SWOT Analysis
Fig. 23 GlaxoSmithKline SWOT Analysis
Fig. 24 Eli Lilly SWOT Analysis
Fig. 25 Pfizer SWOT Analysis
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Age Specific Prevalence of Stable Angina Pectoris in the U.S.+ Top Five EU Markets (Germany, U.K., France, Italy, Spain)
Fig. 8 Age and Gender Specific Prevalence of Stable Angina Pectoris in the U.S.
Fig. 9 Age and Gender Specific Incidence of Stable Angina Pectoris in the U.S.
Fig. 10 Age and Gender Specific Prevalence of Angina Pectoris in the U.K.
Fig. 11 Age and Gender Specific Incidence of Angina Pectoris in the U.K.
Fig. 12 Age and Gender Specific Prevalence of Angina Pectoris in Japan
Fig. 13 Angina Pectoris Treatment Market by Therapeutic Class
Fig. 14 Regional Market Size, 2016 - 2022
Fig. 15 Market Shares Distribution, 2016 - 2022
Fig. 16 Sales by Therapeutic Class, 2016 - 2022
Fig. 17 Branded Sales by Regions, 2016 - 2022
Fig. 18 Angina Pectoris Sector SWOT
Fig. 19 Sanofi SWOT Analysis
Fig. 20 Gilead Sciences SWOT Analysis
Fig. 21 AstraZeneca SWOT Analysis
Fig. 22 Amgen SWOT Analysis
Fig. 23 GlaxoSmithKline SWOT Analysis
Fig. 24 Eli Lilly SWOT Analysis
Fig. 25 Pfizer SWOT Analysis
